Aspirin use in high-risk preeclampsia

The administration of aspirin could be safe and effective in reducing the incidence of preeclampsia with severe features in pregnant individuals.

In a late-breaking abstract (LB02) simultaneously presented at the Society for Maternal-Fetal Medicine 2026 Pregnancy Meeting and published in Pregnancy, researchers examined the outcomes following universal aspirin dispensation among pregnant individuals at moderate and high risk of preeclampsia. The participants were divided into two cohorts: 18,457 patients who delivered prior to the Aug. 3, 2022, implementation of direct aspirin dispensation at 162 milligrams per day and 18,457 patients who received aspirin at their first prenatal appointment at or earlier than 16 weeks of gestation.

Compared with those in the nonaspirin cohort, the researchers found that the participants in the aspirin cohort had a lower rate of preeclampsia with severe features, a longer time to diagnosis, a decreased risk of postpartum hemorrhage and no increased risk of neonatal intraventricular hemorrhage, gastroschisis or placental abruption.

Read more: Pregnancy

The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.